A series of 4,5,6,7-tetrahydro-1H-benzimidazole-5-carboxylic acid and 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-7-carboxylic acid derivatives designed as inhibitors of TAFIa has been prepared via a common hydrogenation-alkylation sequence starting from the appropriate benzimidazole and imidazopyridine system. We present a successful design strategy using a conformational restriction approach resulting in potent and selective inhibitors of TAFIa. The X-ray structure of compound 5 in complex with a H333Y/H335Q double mutant TAFI indicate that the conformational restriction is responsible for the observed potency increase.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmc.2014.02.010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Novel Deep Sea Isoindole Alkaloid FGFC1 Exhibits Its Fibrinolytic Effects by Inhibiting Thrombin-Activatable Fibrinolysis Inhibitor.
Pharmaceuticals (Basel)
October 2024
Department of Marine Bio-Pharmacology, College of Food Science and Technology, Shanghai Ocean University, Shanghai 201306, China.
Background: The thrombin-activatable fibrinolysis inhibitor (TAFI) is an important regulator in the balance between blood clot formation (coagulation) and dissolution (fibrinolysis), which is mainly activated by thrombin bonded with thrombomodulin (TM).
Methods: In this study, the investigation focused on the unique target TAFI of fungi fibrinolytic compound 1 (FGFC1), a novel fibrinolytic compound sourced from the deep sea. In this sense, the regulation of TAFI by FGFC1, in comparison to established TAFI inhibitors such as DS-1040 and PCTI in hPPP, was investigated, which was validated through the molecular docking of FGFC1 to TAFI.
Evaluation of thrombomodulin/thrombin activatable fibrinolysis inhibitor function in plasma using tissue-type plasminogen activator-induced plasma clot lysis time.
Res Pract Thromb Haemost
May 2024
Department of Medical Physiology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
Article Synopsis
- TAFI (thrombin activatable fibrinolysis inhibitor) is an important inhibitor of fibrinolysis, but its effectiveness under normal physiological conditions is still unclear.
- The study aims to understand how the soluble thrombomodulin (sTM) and TAFI work together to regulate the process of fibrinolysis.
- Results showed that the TAFIa inhibitor shortened the time it took for clots to dissolve, while supplementing with rsTM prolonged this time, indicating that the TM/TAFI system plays a significant role in managing fibrinolysis in the bloodstream.
Identification of heparin interaction sites on thrombin-activatable fibrinolysis inhibitor that modulate plasmin-mediated activation, thermal stability, and antifibrinolytic potential.
Res Pract Thromb Haemost
May 2024
Robarts Research Institute, The University of Western Ontario, London, Ontario, Canada.
Background: Thrombin-activatable fibrinolysis inhibitor (TAFI) is a plasma zymogen that provides a molecular link between coagulation and fibrinolysis. Studies have shown that the presence of glycosaminoglycans accelerates TAFI activation by plasmin and stabilizes activated TAFI (TAFIa).
Objectives: We aimed to define the elements of TAFI structure that allow these effects.
Comparative analysis of hyperfibrinolysis with activated coagulation between amniotic fluid embolism and severe placental abruption.
Sci Rep
January 2024
Department of Obstetrics & Gynecology, Hamamatsu University School of Medicine, 1-20-1, Handayama, Higashi-ku, Hamamatsu, 431-3192, Japan.
Article Synopsis
- Amniotic fluid embolism (AFE) and placental abruption (PA) are pregnancy-related conditions linked to severe blood clotting issues known as disseminated intravascular coagulation (DIC).
- AFE tends to have more pronounced fibrinolysis compared to PA and may activate a different mechanism for the fibrinolytic process.
- In a study comparing various coagulation factors in patients with AFE, severe PA, and healthy controls, results showed increased levels of certain markers in both AFE and severe PA, but AFE also exhibited significant changes in specific agents associated with enhanced fibrin breakdown.
Profibrinolytic effects of rivaroxaban are mediated by thrombin-activatable fibrinolysis inhibitor and are attenuated by a naturally occurring stabilizing mutation in enzyme.
J Thromb Thrombolysis
August 2023
Department of Biochemistry, Room 4245A Robarts Research Institute, The University of Western Ontario, 1151 Richmond Street North, London, ON, N6A 5B7, Canada.
Rivaroxaban is a direct factor Xa inhibitor, recently implemented as a favorable alternative to warfarin in anticoagulation therapy. Rivaroxaban effectively reduces thrombin generation, which plays a major role in the activation of thrombin activatable fibrinolysis inhibitor (TAFI) to TAFIa. Based on the antifibrinolytic role of TAFIa, we hypothesized that rivaroxaban would consequently induce more rapid clot lysis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!